Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 3, 2012, Pages 398-403

  Kotagale, Nandkishor R ^a   Taksande, Brijesh G ^a   Wadhwani, Paresh J ^a   Palhade, Mahesh W ^a   Mendhi, Sachin M ^a   Gawande, Dinesh Y ^a   Hadole, Pravin N ^a   Chopde, Chandrabhan T ^a  

^a New Kamptee   (India)

Author keywords

Agmatine; Antipsychotics; Dopamine D2 receptors; Psychosis; Schizophrenia

Indexed keywords

AGMATINE; AMPHETAMINE; APOMORPHINE; HALOPERIDOL; KETAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL RESEARCH; CATALEPSY; CLIMBING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; RAT; SCHIZOPHRENIA;

AGMATINE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DYSKINESIA, DRUG-INDUCED; MALE; MICE; MOLECULAR TARGETED THERAPY; PROLACTIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

ANIMALIA; MUS; RODENTIA;

EID: 80054765622     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.09.006     Document Type: Article

References (74)

1. K.M. Alsene, K. Fallace, and V.P. Bakshi Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine Neuropsychopharmacology 35 12 2010 2346 2356
2. R.C. Andrews The side effects of antimalarial drugs indicate a polyamine involvement in both schizophrenia and depression Med Hypotheses 18 1 1985 11 18 (Pubitemid 15020317)
3. S.A. Andric, A.E. Gonzalez-Iglesias, and F.V. Goor Nitric oxide inhibits prolactin secretion in pituitary cells downstream of voltage-gated calcium influx Endocrinol 144 2003 2912 2921 (Pubitemid 36819894)
4. F. Aricioglu, and H. Altunbas Is agmatine an endogenous anxiolytic/anti-depressant agent? Ann NY Acad Sci 1009 2003 136 140
5. F. Aricioglu-Kartal, and I.T. Uzbay Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats Life Sci 61 1997 1775 1781 (Pubitemid 27440632)
6. J. Arnt Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade Acta Pharmacol Toxicol 51 4 1982 321 329 (Pubitemid 12006638)
7. A.L. Auclair, M.S. Kleven, and C. Barret-Grevoz Differences among conventional, atypical and novel putative D2/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys Behav Brain Res 203 2009 288 295
8. M. Auguet, I. Viossat, and J.G. Marin Selective inhibition of inducible nitric oxide synthase by agmatine Jpn J Pharmacol 69 1995 285 287
9. J.H. Baik, R. Picetti, and A. Saiardi Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors Nature 377 6548 1995 424 428
10. L. Bardin, M.S. Kleven, and C. Barret-Grevoz Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties Neuropsychopharmacol 31 2006 1869 1879
11. L. Bardin, A. Auclair, and M.S. Kleven Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics Behav Pharmacol 18 2 2007 103 118 (Pubitemid 46398960)
12. K. Bence, R. David, and J.P. Stables An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine Pharmacol Biochem Behav 74 2003 771 775 (Pubitemid 36126556)
13. N. Ben-Jonathan Dopamine: a prolactin inhibiting hormone Endocr Rev 6 1985 564 589
14. H. Bernstein, B. Bogerts, and G. Keilhoff The many faces of nitric oxide in schizophrenia. A review Schizophrenia Res 78 2005 69 86 (Pubitemid 41188326)
15. M.D. Black, D.E. Selk, J.M. Hitchcock, J.G. Wettstein, and S.M. Sorensen On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia Neuropharmacology 38 1999 1299 1306 (Pubitemid 29333145)
16. C.L.E. Broekkamp, S.K. Oosterloo, H.H.G. Berendsen, and A.M.L. van Delft Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine Arch Pharmacol 338 1988 191 195
17. S.F. Calderon, P.R. Sanberg, and A.B. Norman Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy Brain Res 450 1988 403 407
18. B. Costall, R.J. Naylor, and V. Nohria Climbing behavior induced by apomorphine in mice: a potential model for the detection of neuroleptic activity Eur J Pharmacol 50 1978 39 50 (Pubitemid 9202912)
19. B. Costall, and R.J. Naylor Mesolimbic involvement with behavioural effects indicating antipsychotic activity Eur J Pharmacol 27 1974 46 58
20. C. Cosi, E. Carilla-Durand, M.B. Assié, A.M. Ormiere, M. Maraval, N. Leduc, and A. Newman-Tancredi Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release Eur J Pharmacol 535 2006 135 144
21. D. Dencker, G. Wörtwein, and P. Weikop Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline J Neurosci 31 16 2011 5905 5908
22. R. Depoortere, L. Bardin, and A.L. Auclair F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) activity in models of positive symptoms of schizophrenia Br J Pharmacol 151 2007 253 265 (Pubitemid 46763036)
23. B.H. Duvilanski, C. Zambruno, and A. Seilicovich Role of nitric oxide in control of prolactin release by the adenohypophysis Proc Natl Acad Sci 92 1995 170 174
24. L. Farde, A.L. Nordstrom, and F.A. Wiesel Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Arch Gen Psychiatry 49 1992 538 544
25. G.M. Gilad, V.H. Gilad, and J.P.M. Finberg Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity Neurochem Res 30 2005 713 719 (Pubitemid 41413930)
26. G.M. Gilad, V.H. Gilad, and M.F. Casanova Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders Biol Psychiatry 38 4 1995 227 234
27. A. Halaris, and J. Plietz Agmatine metabolic pathway and spectrum of activity in brain CNS Drugs 21 11 2007 885 900 (Pubitemid 47557104)
28. D.C. Hoffman, and H. Donovan Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability Psychopharmacol 120 2 1995 128 133
29. J. Hu, J.H. Lee, and E.E. El-Fakahany Inhibition of neuronal nitric oxide synthase by antipsychotic drugs Psychopharmacol 114 1 1994 161 166 (Pubitemid 24150534)
30. R.W. Invernizzi, L. Cervo, and R. Samanin 8-Hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis Neuropharmacology 27 1988 515 518
31. M.M. Iqbal, A. Rahman, and Z. Husain Clozapine: a clinical review of adverse effects and management Ann Clin Psychiatry 15 1 2003 33 48 (Pubitemid 36723639)
32. A.C. Issy, M. Lazzarini, and R.E. Szawka Nitric oxide synthase inhibitors improve prepulse inhibition responses of Wistar rats Behav Brain Res 217 2011 416 423
33. A.C. Issy, C. Salum, and E.A. Del Bel Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice Behav Brain Res 205 2009 475 481
34. S. Kapur, G. Remington, and R.B. Zipursky The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study Life Sci 57 10 1995 103 107
35. S. Kapur, R. Zipursky, and C. Jones A positron emission tomography study of quetiapine in schizophrenia Arch Gen Psychiatry 57 2000 553 559
36. R.T. Khisti, L.S. Deshpande, and C.T. Chopde The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents Psychopharmacol 161 2 2002 120 128 (Pubitemid 34492656)
37. D. Klamer, J.A. Engel, and L. Svensson The neuronal selective nitric oxide synthase inhibitor, N N-propyl-l-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice Eur J Pharmacol 503 2004 103 107 (Pubitemid 39445949)
38. D. Klamer, E. Palsson, and A. Revesz Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms Psychopharmacol 176 2004 440 450 (Pubitemid 40012753)
39. M.S. Kleven, C. Barret-Grevoz, and L.B. Bruins Slot Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats Neuropharmacol 49 2005 135 143 (Pubitemid 40933752)
40. 2- adrenoceptors Behav Brain Res 213 2010 161 174
41. D. Lavinsky, N.S. Arteni, and C.A. Netto Agmatine induces anxiolysis in the elevated plus maze task in adult rats Behav Brain Res 141 1 2003 19 24 (Pubitemid 36382913)
42. S. Leucht, K. Wahlbeck, and J. Hamann New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581 1589 (Pubitemid 36578993)
43. W. Lu, H.J. Dong, and Z.H. Gong Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task Pharmacol Biochem Behav 97 2 2010 256 261
44. S. Ludewig, K. Ludewig, and M.A. Geyer Prepulse inhibition deficits in patients with panic disorder Depress Anxiety 15 2 2002 55 60 (Pubitemid 34252244)
45. H. Meltzer, and B. Massey The role of serotonin receptors in the action of atypical antipsychotic drugs Curr Opin Pharmacol 11 1 2011 Feb 59 67
46. N.A. Moore, D.O. Calligaro, and T.D. Wong The pharmacology of olanzapine and other new antipsychotic agents Curr Opin Invest Drugs 2 1993 281 293
47. G. Olmos, N. DeGregorio-Rocasolano, and M. Paz Regalado Protection by imidazoline drugs and agmatine of glutamate induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor Br J Pharmacol 127 1999 1317 1326 (Pubitemid 29358932)
48. A. Onal, Y. Delen, and S. Ulker Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum Life Sci 73 2004 413 428 (Pubitemid 36577566)
49. O. Ozden, H. Kayir, Y. Ozturk, and T. Uzbay Agmatine blocks ethanol-induced locomotor hyperactivity in male mice Eur J Pharmacol 659 2011 26 29
50. E. Palsson, K. Fejgin, and C. Wass Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition Eur J Pharmacol 590 2008 212 216
51. C.N. Ramchand, I. Das, and A. Gliddon Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls Schizophr Res 13 3 1994 249 253 (Pubitemid 24302655)
52. A. Reif, S. Herterich, and A. Strobel A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function Mol Psychiatry 11 2006 286 300
53. D.J. Reis, and S. Regunathan Is agmatine a novel neurotransmitter in brain? Trends in Pharmacological Sci 21 2000 187 193 (Pubitemid 30243201)
54. G.P. Reynolds, and C. Czudek New approaches to the drug treatment of schizophrenia Adv Pharmacol 32 1995 461 503
55. R.C. Richardson-Andrews A central role for the polyamines in the aetiology of schizophrenia Med Hypotheses 11 2 1983 157 166
56. D.C. Rotaru, H. Yoshino, and D.A. Lewis Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia J Neurosci 31 1 2011 142 156
57. P.R. Sanberg Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors Nature 284 5755 1980 472 473 (Pubitemid 10109053)
58. P. Seeman Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 Neuropsychopharmacol 7 1992 261 283
59. N.R. Swerdlow, J. Paulsen, and D.L. Braff Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease J Neurol Neurosurgery Psychiatry 58 1995 192 200
60. N.R. Swerdlow, C.H. Benbow, and S. Zisook A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder Biol Psychiatry 33 4 1993 298 301 (Pubitemid 23091509)
61. B.G. Taksande, N.R. Kotagale, and M.R. Patel Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats Eur J Pharmacol 637 2010 89 101
62. W.C. Tam, K.W. Sewell, and H.C. Deng Information processing in schizophrenia and bipolar disorder: a discriminant analysis J Nerv Ment Dis 186 10 1998 597 603 (Pubitemid 28477882)
63. R.R. Ugale, K. Hirani, and M. Morelli Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents Neuropsychopharmacol 29 2004 1597 1609 (Pubitemid 39150101)
64. I.T. Uzbay New pharmacological approaches to the treatment of schizophrenia Turk Psikiyatri Derg 20 2 2009 175 182
65. T. Uzbay, H. Kayir, and G. Goktalay Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats J Psychopharmacol 24 2010 923 929
66. T. Uzbay, A. Kose, and H. Kayir Sex-related effects of agmatine on caffeine-induced locomotor activity in Swiss Webster mice Eur J Pharmacol 630 2010 69 73
67. T. Uzbay, O. Yesilyurt, T. Celik, and A. Isimer Effect of agmatine on ethanol withdrawal syndrome in rats Behav Brain Res 107 2000 153 159
68. M.L. Wadenberg, S. Ahlenius, and T.H. Svensson Potency mismatches for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine Psychopharmacol 110 1993 273 279 (Pubitemid 23051127)
69. X.L. Wei, R.B. Su, N. Wu, X.Q. Lu, J.Q. Zheng, and J. Li Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats Eur Neuropsychopharmacol 17 2007 790 799 (Pubitemid 47588863)
70. X.C. Yang, and D.J. Reis Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons J Pharmacol Exp Ther 288 1999 544 549 (Pubitemid 29119663)
71. N. Yilmaz, H. Herken, and H.K. Cicek Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia Med Princ Pract 16 2007 137 141
72. M.Y. Zhu, W.P. Wang, and Z.W. Cai Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain Eur J Neurosci 27 6 2008 1320 1332
73. A.D.E. Zomkowski, L. Hammes, and J. Lin Agmatine produces antidepressant-like effects in two models of depression in mice Neuroscience Report 13 2002 387 391 (Pubitemid 34293175)
74. E. Zomkowski, A. Dias, and A.O. Rosaa Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test Brain Res 1023 2004 253 263